Lasers in healthcare? It’s old news. From laser eye surgery to pain management, laser technology has already made a big impact on the healthcare industry.
Using lasers to cure cancer? That’s a different story. Laser technology has been introduced to help treat cancer, in various ways. Theralase Technologies Inc. (TSXV: TLT, OTCQX: TLTFF, Forum) is going beyond these therapies – way beyond.
The Company’s proprietary laser technology is currently being tested to not merely treat cancer, but to destroy certain forms of cancer. Here it is important to note that this research is targeting internal forms of this dreaded disease that currently provide poor options (and outcomes) for patients.
The Stockhouse audience has already been introduced to Theralase, in a feature article from April 13, 2017. That article posed the question, “Is a Trojan Horse the key to curing cancer?”
Lasers, Trojan Horses, curing cancer – pretty exciting stuff.
The important point for investors is that this is not merely theoretical. TLT has already advanced well beyond the “pre-clinical testing phase”, involving non-human test subjects. The Company is now into full clinical testing – human testing. This is the final “proof of concept” work which is necessary before obtaining regulatory approval and being able to take its potentially revolutionary technology to market.
Stockhouse recently had the opportunity to sit down with the Company’s President and CEO, Roger Dumoulin-White, to hear about the latest developments with this cutting-edge healthcare technology.
FULL DISCLOSURE: Theralase Technologies Inc. is a paid client of Stockhouse Publishing.